COMMUNIQUÉS West-GlobeNewswire

Neuro Salt Ingredients Decoded: Deciphering the Difference Between Official Website Hype & Actual Health Benefits
21/04/2026
A 2026 informational overview of the Neuro Salt nerve health supplement — NeuroSalt supplement facts, botanical ingredient dosages, what the formula contains, how the company presents its research, and what to know [...]
Vapofil Claims Evaluated (2026 Official Website Scam WARNING Update) Avoid Fake Complaints & Hidden Risks
21/04/2026
A 2026 informational overview covering VapoFil ingredient transparency, vapor rub honey trick marketing claims, complaint verification, dosing context against published research, and what consumers searching "is VapoFil [...]
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
21/04/2026
- New data from Phase 2a clinical trial evaluating atebimetinib + mGnP in first-line pancreatic cancer will be presented in an oral session by Dr. Peter Vu, UC San Diego Health - - The ASCO presentation will highlight [...]
CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study
21/04/2026
Enrollment concludes with just over 60 patients participating across seven clinical sites located throughout the United States VANCOUVER, Washington, April 21, 2026 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (" [...]
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
21/04/2026
Data highlight RM-055's ability to overcome resistance and provide deep, durable antitumor activity across preclinical models of pancreatic ductal adenocarcinoma, non-small cell lung cancer and colorectal cancer REDWOOD [...]
Cytokinetics to Announce First Quarter Results on May 5, 2026
21/04/2026
SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report first quarter results on May 5, 2026 at 4:00 PM Eastern Time. [...]
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
21/04/2026
MIAMI, April 21, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2026 after the close of the U.S. financial markets on [...]
Resolutions of the Annual General Meeting 2026 of Bavarian Nordic A/S
21/04/2026
COPENHAGEN, Denmark, April 21, 2026 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results: The Annual Report for 2025 was adopted. The Board of Directors’ proposal to [...]
Precede Biosciences Launches Precede Bio Insight™, a Genome-Wide Liquid Biopsy for Functional Tumor Biology at AACR 2026
21/04/2026
Precede Bio Insight debuts as a first-of-its-kind product enabling genome-wide inference of gene expression, pathway activity, and cell states from just 1 mL of plasma AACR studies demonstrate the ability to predict [...]
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
21/04/2026
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clinical seizures over [...]
Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026
21/04/2026
MENLO PARK, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, [...]
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
21/04/2026
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that safety and tolerability data from the ProstACT Global Phase 3 [...]
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen [...]
Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026
21/04/2026
ZW191 demonstrates encouraging anti-tumor activity in heavily pretreated ovarian and endometrial cancers, regardless of FRα expression Confirmed objective response rate (cORR) of 61% at doses 6.4-9.6 mg/kg in platinum [...]
TELA Bio to Announce First Quarter 2026 Financial Results
21/04/2026
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today [...]
Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026
WOBURN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules targeting RNA and RNA regulation for [...]
Foghorn Therapeutics Presents New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and for Selective CBP, EP300 and ARID1B Degrader Programs at the 2026 AACR Annual Meeting
21/04/2026
- Complete and durable regression and anti-tumor immune memory following treatment with FHD-909 (LY4050784) in combination with an anti-PD-1 antibody in preclinical syngeneic mouse models - Selective CBP degrader FHT- [...]
Oculis Publishes Invitation to the Annual General Meeting
21/04/2026
ZUG, Switzerland, April 21, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), today published the invitation to the 2026 Annual General Meeting, which will be held on May 13, 2026 at Ochsen [...]
BBOT Presents Preclinical Data Showing RAS:PI3Kα Breaker BBO-10203 Inhibits PI3Kα/AKT Signaling in HER2AMP Models at the AACR Annual Meeting 2026
21/04/2026
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to signaling inhibition without inhibiting the kinase activity of PI3Kα and with no observed hyperglycemia BBO-10203 [...]

Pages